| |
Below are all of the recent publications on Waldenstroms macroglobulinemia that our program has assisted in.
Those interested in reading one of the full articles should consult a local medical library for
back issues of the journal in which the article appeared or purchase a reprint online directly from
the journal's web page.
Bortezomib as a Treatment Option in Patients With Waldenstrom Macroglobulinemia
4/6/2010
By M Dimopoulos, C Chen, E Kastritis, M Gavriatopoulou, SP Treon
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
3/10/2010
By IM Ghobrial, MA Gertz , B LaPlant, J Camoriano, S Hayman, M Lacy, S Chuma, B Harris, R Leduc, M Rourke, S Ansell, D DeAngelo, A Dispenzieri, L Bergsagel, C Reeder, KC Anderson, P Richardson, SP Treon, TE Witzig
Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia
3/10/2010
By IM Ghobrial, F Hong, S Padmanabhan, A Badros, M Rourke, R Leduc, S Chuma, J Kunsman, D Warren, B Harris, A Sam, KC Anderson, P Richardson, SP Treon, E Weller, J Matous
IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia
11/10/2009
By ZR Hunter, R Manning, C Hanzis, B Ciccarelli, L Ioakimidis, C Patterson, M Lewicki, H Tseng, P Gong, X Liu, Y Zhou, G Yang, J Sun, L Xu, P Sheehy, M Morra, SP Treon
How I Treat Waldenstrom's Macroglobulinemia
7/17/2009
By Steven Treon
Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
6/8/2009
By SP Treon, L Ioakimidis, J Soumerai, C Patterson, P Sheehy, M Nelson, MA Willen, J Matous, J Mattern II, J Diener, G Keogh, TJ Myers, A Boral, A Birner, DL Esseltine, IM Ghobrial
Soluble CD27 Is a Faithful Marker of Disease Burden and Is Unaffected by the Rituximab-Induced IgM Flare, as Well as by Plasmapheresis, in Patients with Waldenström's Macroglobulinemia.
3/18/2009
By B Ciccarelli, G Yang, E Hatjiharissi, L Ioakimidis, C Patterson, R Manning, L Xu, X Liu, H Tseng, P Gong, J Sun, Y Zhou, SP Treon
Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden.
3/18/2009
By SP Treon, C Patterson, E Kimby , M Stone
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia.
2/6/2009
By X Leleu, ZR Hunter, L Xu, AM Roccaro, AS Moreau, DD Santos, E Hatjiharissi, V Bakthavachalam, S Adamia, AW Ho, J Soumerai, C Patterson, R Manning, S Hamilton, S Verselis, EA Fox, R Carrasco, J Ghobrial, SP Treon
International prognostic scoring system for Waldenstrom's macroglobulinemia.
2/5/2009
By P Morel , A Duhamel, P Gobbi, M Dimopoulos, M Dhodapkar , J McCoy, J Crowley, E Ocio, R Garcia-Sanz, SP Treon, V Leblond , R Kyle, B Barlogie , G Merlini
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs
12/8/2008
By X Leleu, J Soumerai, AM Roccaro, E Hatjiharissi, ZR Hunter, R Manning, B Ciccarelli, A Sacco, L Ioakimidis, S Adamia, AS Moreau, C Patterson, J Ghobrial, SP Treon
Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia
12/8/2008
By M Dimopoulos, MA Gertz , E Kastritis, R Garcia-Sanz, E Kimby , V Leblond , JP Fermand, G Merlini , P Morel , E Morra , E Ocio, RG Owen , J Ghobrial, J Seymour, R Kyle, SP Treon
Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with Familial Waldenström’s Macroglobulinemia.
12/8/2008
By ZR Hunter, L Ioakimidis, J Soumerai, C Patterson, L Xu, X Leleu, B Ciccarelli, A Sacco, S Adamia, E Hatjiharissi, SP Treon
Comparative Outcomes following CP-R, CVP-R and CHOP-R in patients with Waldenstrom’s Macroglobulinemia.
12/6/2008
By L Ioakimidis, C Patterson, J Soumerai, R Manning, P Sheehy, SP Treon
5-Azacytidine inhibits the mammalian target of rapamycin complex 1 signal and induces apoptosis in Waldenstrom’s macroglobulinemia
12/6/2008
By L Xu, B Ciccarelli, E Hatjiharissi, S Adamia, Y Zhou, J Sun, G Yang, H Tseng, X Liu, L Ioakimidis, R Manning, C Patterson, SP Treon
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstrom’s Macroglobulinemia.
12/6/2008
By J Sun, L Xu, H Tseng, B Ciccarelli, M Fulciniti, E Hatjiharissi, Y Zhou, G Yang, X Liu, L Ioakimidis, P Sheehy, R Manning, C Patterson, N Munshi, O O'Connor, SP Treon
Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia.
11/17/2008
By SP Treon, AR Branagan, L Ioakimidis, J Soumerai, C Patterson, B Turnbull, P Wasi, C Emmanouilides , S Frankel , TA Lister , P Morel , J Matous, SA Gregory, E Kimby
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.
11/3/2008
By X Leleu, L Xu, X Jia, A Sacco, M Farag, ZR Hunter, AS Moreau, HT Ngo, E Hatjiharissi, AW Ho, DD Santos, S Adamia, KE O'Connor, B Ciccarelli, J Soumerai, R Manning, C Patterson, AM Roccaro, IM Ghobrial, SP Treon
High-throughput microRNA profiling: Identification of miRNAs with a potential pathogenetic role in Waldenström's macroglobulinemia.
10/15/2008
By S Adamia, S Amin, C Patterson, P Moreau, S Minvielle, C Li, H AvetLoiseau, KC Anderson, N Munshi, SP Treon
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia.
9/15/2008
By AS Moreau, X Jia, C Patterson, AM Roccaro, L Xu, A Sacco, KE O'Connor, J Soumerai, HT Ngo, E Hatjiharissi, ZR Hunter, B Ciccarelli, R Manning, IM Ghobrial, X Leleu, SP Treon
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.
7/1/2008
By HT Ngo, X Leleu, J Lee, X Jia, M Melhem, J Runnels, AS Moreau, N Burwick, A Azab, AM Roccaro, F Azab, A Sacco, M Farag, R Sackstein, IM Ghobrial
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
6/16/2008
By X Leleu, AS Moreau, E Weller, AM Roccaro, V Coiteux, R Manning, M Nelson, R Leduc, D Robu, S Dupire, E Hatjiharissi, N Burwick, S Darre, B Hennache, SP Treon, T Facon, MA Gertz , IM Ghobrial
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
6/15/2008
By AS Moreau, Y Sebti, A Duhamel, AM Roccaro, V Coiteux, T Gastinne, G LeFriec, N Burwick, L Amiot, AW Ho, S Poulain, B Hennache, ZR Hunter, JP Dessaint, IM Ghobrial, SP Treon, T Facon, E Zorn, X Leleu
Targeted therapies in Waldenström macroglobulinemia.
6/9/2008
By N Burwick, AM Roccaro, X Leleu, IM Ghobrial
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
5/15/2008
By X Leleu, J Eeckhoute, X Jia, AM Roccaro, AS Moreau, M Farag, A Sacco, HT Ngo, J Runnels, M Melhem, N Burwick, A Azab, F Azab, ZR Hunter, E Hatjiharissi, R Carrasco, SP Treon, TE Witzig, T Hideshima, M Brown, KC Anderson, IM Ghobrial
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
5/1/2008
By AM Roccaro, X Leleu, A Sacco, X Jia, M Melhem, AS Moreau, HT Ngo, J Runnels, A Azab, F Azab, N Burwick, M Farag, SP Treon, M Palladino, T Hideshima, D Chauhan , KC Anderson, IM Ghobrial
Resveratrol exerts antiproliferative effects and induces apoptosis in Waldenstrom’s Macroglobulinemia
3/15/2008
By AM Roccaro, X Leleu, AS Moreau, C Patterson, L Xu, A Jia, H N'Go, A Sacco, Y Cao, B Ciccarelli, R Manning, S Adamia, E Hatjiharissi, D Russo, A Vacca, F Dammacco, IM Ghobrial, SP Treon
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
3/1/2008
By MN Menke, GT Feke, JW McMeel, SP Treon
CD27-CD70 interactions in the pathogenesis of Waldenstrom’s Macroglobulinemia
1/23/2008
By AW Ho, E Hatjiharissi, AR Branagan, ZR Hunter, X Leleu, O Tournilhac, L Xu, KE O'Connor, R Manning, DD Santos, MZ Chemaly, B Ciccarelli, C Patterson, J Soumerai, N Munshi, J McEarchern, C Law, IS Grewal , SP Treon
Increased natural killer cell expression of CD16 and augmented binding and ADCC activity to rituximab among individuals expressing the Fc gamma RIIIA-158 V/V and V/F polymorphism
10/1/2007
By E Hatjiharissi, L Xu, DD Santos, ZR Hunter, B Ciccarelli, S Verselis, M Modica, Y Cao, R Manning, X Leleu, EA Dimmock, A Kortsaris, C Mitsiades, KC Anderson, EA Fox, SP Treon
Genetic linkage of Fc gammaRIIa and Fc gammaRIIIa and implications for their use in predicting clinical responses to CD20 directed monoclonal antibody therapy
10/1/2007
By E Hatjiharissi, M Hansen, DD Santos, L Xu, X Leleu, EA Dimmock, A Ho, ZR Hunter, AR Branagan, C Patterson, A Kortsaris, S Verselis, EA Fox, SP Treon
Establishment of BCWM.1 cell line for Waldenstrom’s Macroglobulinemia with productive in vivo engraftment in SCID-hu mice
9/1/2007
By DD Santos, AW Ho, O Tournilhac, E Hatjiharissi, X Leleu, L Xu, P Tassone, P Neri, ZR Hunter, MZ Chemaly, AR Branagan, R Manning, C Patterson, AS Moreau, B Ciccarelli, S Adamia, J Kriangkum , J Kutok, YT Tai , J Zhang, LM Pilarski , KC Anderson, N Munshi, SP Treon
Novel agents in the treatment of Waldenström's macroglobulinemia
8/1/2007
By SP Treon, E Hatjiharissi, X Leleu, AS Moreau, AM Roccaro, ZR Hunter, J Soumerai, B Ciccarelli, L Xu, A Sacco, H N'Go, X Jia, C Yang, S Adamia, AR Branagan, AW Ho, DD Santos, O Tournilhac, R Manning, R Leduc, KE O'Connor, M Nelson, C Patterson, IM Ghobrial
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom’s Macroglobulinemia
6/1/2007
By SP Treon, ZR Hunter, J Matous, RM Joyce, B Mannion, R Advani, D Cook, J Songer, J Hill, BR Kaden, D Sharon, R Steiss, X Leleu, AR Branagan, A Badros
Proteomic analysis of Waldenstrom Macroglobulinemia
4/1/2007
By E Hatjiharissi, H N'Go, A Leontovich, X Leleu, M Timm, M Melhem, D George, G Lu, J Ghobrial, Y Alsayed, S Zeismer, M Cabela, A Nehme, A Jia, AS Moreau, SP Treon, R Fonseca , MA Gertz , KC Anderson, TE Witzig, IM Ghobrial
Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia
1/1/2007
By X Leleu, KE O'Connor, A Ho, DD Santos, R Manning, L Xu, E Hatjiharissi, O Tournilhac, MZ Chemaly, AR Branagan, ZR Hunter, C Patterson, KC Anderson, SP Treon
Accumulation of Inherited and Acquired Mutations in Hyaluronan Synthase1 Gene May Contribute Oncogenesis in Multiple Myeloma and Waldenstroms Macroglobulinemia.
12/11/2006
By S Adamia, J Hodges, PM Pilarski, SP Treon, MJ Mant , T Reiman, AR Belch
Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstroms Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.
12/10/2006
By SP Treon, J Soumerai, C Patterson, ZR Hunter, IM Ghobrial, R Villarreal, MA Willen, TJ Myers
Imatinib Mesylate (Gleevec) Is Active in Relapsed/Refractory Waldenstroms Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.
12/10/2006
By SP Treon, J Soumerai, C Patterson, ZR Hunter, R Villarreal, IM Ghobrial
Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrms Macroglobulinemia (WM).
12/10/2006
By E Hatjiharissi, AW Ho, L Xu, KE O'Connor, ZR Hunter, DD Santos, R Manning, AS Moreau, C Patterson, J McEarchern, C Law, IS Grewal , N Munshi
Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.
12/10/2006
By X Leleu, X Jia, AS Moreau, E Hatjiharissi, H Ngo, D Moreno, T Kiziltepe, G O'Sullivan, E Ocio, AW Ho, T Facon, T Hideshima, K Anderson
The Selective Protein Kinase C Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstroms Macroglobulinemia.
12/10/2006
By AS Moreau, X Jia, G O'Sullivan, X Leleu, K Podar , E Hatjiharissi, S Lalo, H Ngo, M Raab, JC D'Halluin, T Facon, T Hideshima, SP Treon, K Anderson, IM Ghobrial
Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstroms Macroglobulinemia, the Role of the ERK and PKC Pathways.
12/10/2006
By X Leleu, H Ngo, X Jia, AS Moreau, E Hatjiharissi, R Carrasco, G O'Sullivan, J Runnels, YT Tai , SP Treon, T Hideshima, K Anderson, IM Ghobrial
International Prognostic Scoring System (IPSS) for Waldenstrms Macroglobulinemia (WM).
12/10/2006
By P Morel , A Duhamel, P Gobbi, M Dimopoulos, M Dhodapkar , J McCoy, E Ocio, R Garcia-Sanz, SP Treon, V Leblond , R Kyle, B Barlogie , G Merlini
Accumulation of Inherited and Acquired Mutations in Hyaluronan Synthase1 Gene May Contribute Oncogenesis in Multiple Myeloma and Waldenstroms Macroglobulinemia.
12/10/2006
By S Adamia, J Hodges, PM Pilarski, SP Treon, MJ Mant , T Reiman, AR Belch , LM Pilarski
The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.
12/10/2006
By H Ngo, E Hatjiharissi, J Runnels, AS Moreau, X Leleu, G O'Sullivan, DD Santos, L Xu, SP Treon, T Hideshima, K Anderson, IM Ghobrial, X Jia
The PI3K/Akt Pathway Is an Important Regulator of Homing and Adhesion in Waldenstroms Macroglobulinemia
11/16/2006
By X Leleu, H Ngo, C Pitsillides, J Spencer, J Runnels, AS Moreau, E Hatjiharissi, X Jia, G O'Sullivan, SP Treon, T Hideshima, B Lin , K Anderson, IM Ghobrial
Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstroms Macroglobulinemia.
11/16/2006
By X Leleu, G O'Sullivan, X Jia, AS Moreau, H Ngo, E Hatjiharissi, H Yasui, ZR Hunter, YT Tai , J Runnels, SP Treon, T Hideshima, K Anderson, IM Ghobrial
Serum Free Light Chain in Waldenstrom Macroglobulinemia.
11/16/2006
By AS Moreau, X Leleu, R Manning, V Coiteux, S Darre, E Hatjiharissi, ZR Hunter, X Jia, H Ngo, G O'Sullivan, DD Santos, SP Treon, T Facon, K Anderson, IM Ghobrial
Endoplasmic Reticulum Stress Is a Target for Therapy in Waldenstroms Macroglobulinemia (WM).
11/16/2006
By X Leleu, L Xu, ZR Hunter, X Jia, AS Moreau, AW Ho, E Hatjiharissi, H N'Go, DD Santos, KE O'Connor, R Manning, J Soumerai, C Patterson, SP Treon
Abnormal Expression of TRAF Adapter Proteins in Waldenstroms Macroglobulinemia.
11/16/2006
By X Leleu, L Xu, ZR Hunter, AS Moreau, X Jia, G O'Sullivan, V Bakthavachalam, AW Ho, E Hatjiharissi, H Ngo, DD Santos, KE O'Connor, R Manning, J Soumerai, C Patterson, IM Ghobrial
IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstroms Macroglobulinemia (WM).
11/16/2006
By ZR Hunter, X Leleu, E Hatjiharissi, DD Santos, L Xu, AW Ho, V Bakthavachalam, AS Moreau, KE O'Connor, J Soumerai, C Patterson, IM Ghobrial, S Hamilton, S Verselis, EA Fox
Analysis of Chemokine and Adhesion Markers in Waldenstrom Macroglobulinemia.
11/16/2006
By H Ngo, X Leleu, AS Moreau, E Hatjiharissi, X Jia, G O'Sullivan, J Runnels, ZR Hunter, SP Treon, T Hideshima, K Anderson, IM Ghobrial
Molecular Characterization of Clonotypic VDJ Sequences in Waldenstroms Macroglobulinemia Suggests Independent Transformation Events in the Development of Biclonal B Cells.
11/16/2006
By J Kriangkum , BJ Taylor, SP Treon, MJ Mant , T Reiman, AR Belch , LM Pilarski
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.
11/16/2006
By X Leleu, AS Moreau, E Hatjiharissi, H Ngo, G O'Sullivan, SP Treon, C Mitsiades, T Hideshima, D Chauhan, T Hideshima, KC Anderson, D Chauhan , IM Ghobrial, M Palladino, K Anderson
Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstroms Macroglobulinemia (WM).
11/16/2006
By C Patterson, AS Moreau, X Leleu, J Soumerai, ZR Hunter, E Hatjiharissi, L Xu
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.
11/16/2006
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.
11/16/2006
The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.
11/16/2006
By J Xiaoying , X Leleu, AS Moreau, E Hatjiharissi, H Ngo, G O'Sullivan, D McMillin, C Mitsiades, T Hideshima, M Palladino, K Anderson, D Chauhan , IM Ghobrial
Hyperviscosity-related retinopathy in Waldenstrom’s Macroglobulinemia
11/1/2006
By MN Menke, GT Feke, JW McMeel, AR Branagan, ZR Hunter, SP Treon
Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling
6/20/2006
By O Tournilhac, DD Santos, L Xu, J Kutok, YT Tai , S Le Gouill, L Catley, ZR Hunter, AR Branagan, J Boyce, N Munshi, KC Anderson, SP Treon
Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia
6/20/2006
By C Patterson, J Soumerai, ZR Hunter, X Leleu, IM Ghobrial, SP Treon
Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079
6/20/2006
By ZR Hunter, M Boxer, B Kahl, C Patterson, J Soumerai, SP Treon, On behalf of the WMCTG
Therapeutic targeting of CD70 and CD27-CD70 interactions with the monoclonal antibody SGN-70 in Waldenstrom's Macroglobulinemia (WM).
6/20/2006
By AW Ho, E Hatjiharissi, AR Branagan, ZR Hunter, J McEarchern, C Law, IS Grewal , DD Santos, YT Tai , SP Treon
CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders
5/6/2006
By DD Santos, E Hatjiharissi, O Tournilhac, MZ Chemaly, X Leleu, L Xu, C Patterson, AR Branagan, R Manning, AW Ho, ZR Hunter, EA Dimmock, J Kutok, WH Churchill, M Catsells, YT Tai , KC Anderson, SP Treon
Update on treatment recommendations from the Third International Workshop on Waldenstrom’s Macroglobulinemia
5/1/2006
By SP Treon, MA Gertz , M Dimopoulos, A Anagnostopoulos , J Blade , AR Branagan, R Garcia-Sanz, S Johnson, E Kimby , V Leblond , JP Fermand, D Maloney, G Merlini , P Morel , E Morra , G Nichols, E Ocio, RG Owen , M Stone
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom’s Macroglobulinemia
3/1/2006
By E Kimby , SP Treon, A Anagnostopoulos , M Dimopoulos, R Garcia-Sanz, MA Gertz , S Johnson, V Leblond , JP Fermand, D Maloney, G Merlini , P Morel , E Morra , G Nichols, E Ocio, RG Owen , M Stone , J Blade
Characterization of familial Waldenstrom’s Macroglobulinemia
3/1/2006
By SP Treon, ZR Hunter, A Aggarwal, EP Ewen, S Masotta, C Lee, DD Santos, E Hatjiharissi, L Xu, X Leleu, O Tournilhac, C Patterson, R Manning, AR Branagan, C Morton
Update on treatment recommendations from the Third International Workshop on Waldenstrom's Macroglobulinemia
1/1/2006
By SP Treon, MA Gertz , M Dimopoulos, A Anagnostopoulos , J Blade , AR Branagan, R Garcia-Sanz, S Johnson, E Kimby , V Leblond , JP Fermand, D Maloney, G Merlini , P Morel , E Morra , G Nichols, E Ocio, RG Owen , M Stone
Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström's Macroglobulinemia: Preliminary Safety and Efficacy Results
12/13/2005
By SP Treon, ZR Hunter, C Patterson, AR Branagan
Role of Chemokine Receptor CXCR4 in Waldenstrom's Macroglobulinemia
12/13/2005
By IM Ghobrial, M Melhem, U Singha, D George, M Timm, L Francis, Y Alsayed, A Huston, GD Roodman, PR Greipp , MA Gertz
Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) Using Nanoscale Protein Micorarray Techniques
12/13/2005
By Y Alsayed, M Timm, A Leontovich, DD Santos, AW Ho, U Singha, L Francis, A Huston, G Lu, S Lentzsch , GD Roodman, X Leleu, SP Treon, IM Ghobrial
Polymorphisms in FcγRIIIA Are Genetically Linked to FcγRIIA and May Account for the Primary Predictive Role Ascribed to Polymorphisms in FcγRIIIA-158 in Determining Rituximab Responses
12/13/2005
By E Hatjiharissi, M Hansen, S Verselis, DD Santos, L Xu, R Manning, ZR Hunter, X Leleu, AW Ho, C Patterson, EA Fox, SP Treon
Sequence Analysis in the BLYS and APRIL Receptor TACI Reveals Novel Variants with a Potential Pathogenetic Role in Waldenstrom's Macroglobulinemia (WM).
12/11/2005
By ZR Hunter, X Leleu, DD Santos, S Hamilton, S Verselis, EA Fox, IS Grewal , SP Treon
Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenstrom's Macroglobulinemia
12/10/2005
By L Xu, X Leleu, ZR Hunter, DD Santos, AW Ho, E Hatjiharissi, KE O'Connor, R Manning, MZ Chemaly, AR Branagan, C Patterson, S Verselis, EA Fox, KC Anderson, SP Treon
Single Nucleotide Polymorphisms (SNPs) and Recurrent Mutations in the Hyaluronan Synthase 1 (HAS1) Gene May Predispose to Multiple Myeloma (MM) and Waldenstrom's Macroglobulinemia (WM)
12/10/2005
By S Adamia, SP Treon, DD Santos, ZR Hunter, MJ Mant , T Reiman, AR Belch , LM Pilarski
Thalidomide in Combination with Rituximab Is Active in Waldenström's Macroglobulinemia and May Overcome Poor Response Determinants Associated with Rituximab Monotherapy
12/10/2005
By SP Treon, ZR Hunter, C Patterson, AR Branagan
Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice
12/10/2005
By DD Santos, AW Ho, O Tournilhac, X Leleu, E Hatjiharissi, L Xu, P Tassone, P Neri, ZR Hunter, MZ Chemaly, AR Branagan, R Manning, S Adamia, J Kriangkum , J Kutok, LM Pilarski , KC Anderson, N Munshi, SP Treon
A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom's Macroglobulinemia
12/9/2005
By AW Ho, X Leleu, E Hatjiharissi, O Tournilhac, L Xu, KE O'Connor, R Manning, DD Santos, MZ Chemaly, AR Branagan, ZR Hunter, C Patterson, KC Anderson, SP Treon, J Kutok
The Unfolded Protein Response Is a Determinant of Disease Actvity in Waldenstrom's Macroglobulinemia (WM)
12/9/2005
By X Leleu, L Xu, DD Santos, AW Ho, ZR Hunter, KE O'Connor, R Manning, O Tournilhac, MZ Chemaly, AR Branagan, KC Anderson, SP Treon
Individuals Expressing FcgRIIIa-158 V/V and V/F Show Increased NK Cell Surface Expression of FcgRIIIa (CD16) and Rituximab Binding and Demonstrate Higher Levels of ADCC Activity in Response to Rituximab
12/9/2005
By E Hatjiharissi, DD Santos, L Xu, S Verselis, M Modica, X Leleu, ZR Hunter, AW Ho, R Manning, C Patterson, KC Anderson, EA Fox, SP Treon
Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response
12/9/2005
By DD Santos, MZ Chemaly, O Tournilhac, KE O'Connor, E Hatjiharissi, X Leleu, L Xu, AR Branagan, R Manning, C Patterson, AW Ho, ZR Hunter, JM You, YT Tai , J Kutok, KC Anderson, N Munshi, SP Treon
CHOP plus Rituximab Therapy in Waldenstrom's Macroglobulinemia.
3/1/2005
By SP Treon, ZR Hunter, AR Branagan
CD5, CD10, and CD23 Expression in Waldenstrom's Macroglobulinemia.
3/1/2005
By ZR Hunter, AR Branagan, R Manning, C Patterson, DD Santos, O Tournilhac, M Dorfman, SP Treon
Potential Impact of a Single Nucleotide Polymorphism in the Hyaluronan Synthase 1 Gene in Waldenstrom's Macroglobulinemia.
3/1/2005
By S Adamia, SP Treon, T Reiman, O Tournilhac, C McQuarrie, MJ Mant , AR Belch , LM Pilarski
Polymorphisms in FcRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia
3/1/2005
By SP Treon, M Hansen, AR Branagan, S Verselis, C Emmanouilides , E Kimby , S Frankel , N Touroutoglou, B Turnbull, KC Anderson, D Maloney, EA Fox
High levels of soluble immunoregulatory receptors in patients with Waldenstrom’s macroglobulinemia.
12/16/2004
By ZR Hunter, AR Branagan, DD Santos, O Tournilhac, E Hatjiharissi, L Xu, R Manning, SP Treon
IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenstrom’s Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions
12/16/2004
By SP Treon, AR Branagan, ZR Hunter, DD Santos, O Tournilhac, E Hatjiharissi, L Xu, R Manning
Mutator Genes UDG and AID Appear To Be Normal in Class-Switch Deficient and Clonally Homogeneous Waldenstrom's Macroglobulinemias Having Either Germline or Hypermutated Clonotypic IgH VDJ.
12/15/2004
By J Kriangkum , BJ Taylor, E Strachan, SP Treon, MJ Mant , T Reiman, AR Belch , LM Pilarski
Polymorphisms in the Hyaluronan Synthase 1 Gene May Be Predisposing Factors for Waldenstrom’s Macroglobulinemia.
12/15/2004
By S Adamia, SP Treon, MJ Mant , L Larratt, T Reiman, AR Belch , LM Pilarski
Thalidomide and Rituximab in Waldenström’s Macroglobulinemia.
12/15/2004
By AR Branagan, ZR Hunter, DD Santos, J Moran, SP Treon
Constitutive Expression of CD40L on Bone Marrow Mast Cells Supports the Growth of Lymphoplasmacytic Cells in Patients with Waldenstrom’s Macroglobulinemia
12/15/2004
By O Tournilhac, DD Santos, L Xu, J Kutok, YT Tai , S Le Gouill, E Hatjiharissi, L Catley, ZR Hunter, AR Branagan, KC Anderson, SP Treon
A Novel Murine Model for Human Waldenstrom’s Macroglobulinemia.
12/15/2004
By P Tassone, P Neri, J Kutok, O Tournilhac, DD Santos, E Hatjiharissi, S Venuta, KC Anderson, SP Treon, N Munshi
CD52 Is Expressed on Human Mast Cells and Is a Therapeutic Target for the Anti-CD52 Monoclonal Antibody Campath-1H in Waldenstrom’s Macroglobulinemia and Mast Cell Disorders
12/15/2004
By DD Santos, E Hatjiharissi, O Tournilhac, L Xu, AR Branagan, ZR Hunter, M Catsells, KC Anderson, SP Treon
Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenstrom's Macroglobulinemia.
12/15/2004
By O Tournilhac, S Le Gouill, DD Santos, K Podar , L Xu, E Hatjiharissi, YT Tai , ZR Hunter, AR Branagan, KC Anderson, SP Treon
Campath-1H in Waldenström’s Macroglobulinemia.
12/15/2004
By ZR Hunter, AR Branagan, SP Treon
Clinical Responses to Sildenafil in Waldenstrom’s Macroglobulinemia.
12/15/2004
By SP Treon, O Tournilhac, AR Branagan, ZR Hunter, L Xu, E Hatjiharissi, DD Santos
Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenstrom’s Macroglobulinemia.
12/15/2004
By O Tournilhac, DD Santos, L Xu, E Hatjiharissi, YT Tai , L Catley, ZR Hunter, AR Branagan, R Burger, R Shringarpure, J Boyce, KC Anderson, SP Treon
CHOP Plus Rituximab (CHOP-R) in Waldenström’s Macroglobulinemia (WM).
12/15/2004
By ZR Hunter, AR Branagan, SP Treon
Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.
12/15/2004
By SP Treon, AR Branagan, P Wasi, C Emmanouilides , S Frankel , TA Lister , P Morel , J Matous, S Enschede, E Kimby
B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenstrom’s Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.
12/15/2004
By DD Santos, O Tournilhac, L Xu, E Hatjiharissi, ZR Hunter, AR Branagan, R Manning, KC Anderson, IS Grewal , SP Treon
Heterogeneous expression of CD5, CD10, and CD23 in Waldenstrom’s macroglobulinemia.
6/5/2004
By T. Cafarella, R Manning, ZR Hunter, AR Branagan, O Tournilhac, DD Santos, SP Treon
Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom’s macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway.
6/5/2004
By O Tournilhac, DD Santos, AR Branagan, ZR Hunter, R Manning, YT Tai , J Kutok, N Munshi, KC Anderson, SP Treon
Characterization of familial Waldenstrom’s Macroglobulinemia.
6/5/2004
By R Manning, AR Branagan, ZR Hunter, O Tournilhac, DD Santos, SP Treon
Polymorphisms in FcGRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia.
6/5/2004
By SP Treon, M Hansen, AR Branagan, C Emmanouilides , E Kimby , S Frankel , N Touroutoglou, D Maloney, KC Anderson, EA Fox
Deletions in 6q21-22 Are Commonly Present in Patients with Familial and Non-Familial Waldenstroms Macroglobulinemia and IgM Monoclonal Gammopathy of Unknown Significance (MGUS).
12/7/2003
By SP Treon, E Braverman, AR Branagan, S Masotta, M Listewnik, C Morton, C Lee
Paradoxical Increases in Serum IgM Levels and Serum Viscosity Following Rituximab Therapy in Patients with Waldenstroms Macroglobulinemia (WM).
12/7/2003
By SP Treon, AR Branagan, KC Anderson
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
5/1/2003
By T Hayashi , SP Treon, T Hideshima, YT Tai , M Akiyama , P Richardson, D Chauhan , IS Grewal , KC Anderson
Novel biologically based therapies for Waldenstrom's macroglobulinemia
4/30/2003
By C Mitsiades, N Mitsiades, P Richardson, SP Treon, KC Anderson
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
4/30/2003
By MA Gertz , A Anagnostopoulos , KC Anderson, AR Branagan, M Coleman , S Frankel , T Levine, N Munshi, A Pestronk , V Rajkumar , SP Treon
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
4/30/2003
By R Kyle, SP Treon, R Alexanian , B Barlogie , M Bjorkholm , M Dhodapkar , TA Lister , G Merlini , P Morel , M Stone , AR Branagan, V Leblond
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
4/30/2003
By RG Owen , SP Treon, A Al-Katib , R Fonseca , PR Greipp , ML McMaster , E Morra , GA Pangalis , JF San Miguel , AR Branagan, M Dimopoulos
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
4/1/2003
By D Weber , SP Treon, C Emmanouilides , AR Branagan, JC Byrd , J Blade , E Kimby
The malignant clone in Waldenstrom's macroglobulinemia.
4/1/2003
By J Kriangkum , BJ Taylor, MJ Mant , SP Treon, AR Belch , LM Pilarski
Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias
4/1/2003
By C Mitsiades, N Mitsiades, SP Treon, KC Anderson
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations
4/1/2003
By SP Treon, A Kelliher , B Keele , S Frankel , C Emmanouilides , E Kimby , R Schlossman , N Mitsiades, C Mitsiades, F Preffer , KC Anderson
Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
5/15/2002
By N Mitsiades, C Mitsiades, V Poulaki, KC Anderson, SP Treon
The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders.
12/27/2001
By SP Treon, KC Anderson
Immunotherapeutic strategies for the treatment of plasma cell malignancies.
10/27/2001
By SP Treon, N Raje , KC Anderson
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
10/26/2001
By SP Treon, Y Shima, F Preffer , DS Doss , L Ellman , R Schlossman , ML Grossbard , AR Belch , LM Pilarski , KC Anderson
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
8/10/2001
By N Mitsiades, C Mitsiades, V Poulaki, KC Anderson, SP Treon
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
8/1/2001
By C Mitsiades, SP Treon, N Mitsiades, Y Shima, P Richardson, R Schlossman , T Hideshima, KC Anderson
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
6/1/2001
By FE Davies , N Raje , T Hideshima, S Lentzsch , G Young , YT Tai , B Lin , K Podar , D Gupta , D Chauhan , SP Treon, P Richardson, R Schlossman , GJ Morgan , GW Muller , DI Stirling , KC Anderson
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
5/24/2001
By SP Treon, DB Angus, B Link, G Rodrigues, A Molina , MQ Lacy, DC Fisher, C Emmanouilides , AI Richards , B Clark, MS Lucas, R Schlossman , D Schenkein , B Lin , E Kimby , KC Anderson, JC Byrd
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
5/24/2001
By SP Treon, C Mitsiades, N Mitsiades, G Young , DS Doss , R Schlossman , KC Anderson
<< Back
|
|
